Translated with AI
On April 1, 2026, Health Canada published the “Guidance on terms and conditions for class II to IV Medical Devices” , which defines the operational procedures by which the Authority applies, amends, or removes Terms and Conditions (T&Cs) related to Class II, III, and IV Medical Device licenses. The guidance provides clarifications on the provisions introduced by the amendments to the Medical Device Regulations, which were adopted in late 2025 and entered into force on January 1, 2026.
What are Terms and Conditions (T&Cs)?
In the Canadian regulatory context, T&Cs are specific and binding obligations that Health Canada attaches to a Medical Device Licence. They act as supplemental requirements that the manufacturer must satisfy to maintain their product on the market.
As of January 1, 2026, with the entry into force of the amendments to the Medical Devices Regulations, the Authority has acquired the power to link license validity to post-market surveillance and monitoring activities (rather than just at the time of initial issuance), such as:
- Post-market clinical studies: the obligation to provide follow-up data on a defined number of patients within set deadlines.
- Supplemental testing: requests for additional stability or biocompatibility evidence.
- Restrictions on use: limitations on distribution or specific training requirements for users.
- Targeted monitoring: close surveillance of potential specific adverse events.
It is important to emphasize that failure to comply with these terms, which are now applicable at any time, can result in the immediate suspension of the license.
The Regulatory framework: the reform in effect
The publication of this technical guidance on April 1 is not an isolated event, but a tool to operationally manage the legislative reform already fully effective since January 1, 2026. This reform introduced a substantial change:
- Temporal flexibility: Health Canada is no longer limited to imposing conditions only at the time of license issuance but can do so at any point during the device’s lifecycle.
- Dynamic corrective power: the Authority now has the legal basis to intervene in existing and active licenses should new risk signals emerge during post-market clinical use.
What changes concretely with this edition of the guidance?
The April 1, 2026, guidance details the processes through which Health Canada intends to exercise the new authorities over T&Cs introduced by the January regulatory amendments. operational updates include:
- Post-market notification process: the formal procedure by which Health Canada communicates its intention to add T&Cs to an active license, including the manufacturer’s right to submit observations.
- Removal parameters: clear criteria under which a manufacturer can request the cancellation of a condition once the required data has been provided.
- Transparency and proportionality: a standardized process to ensure that the Authority’s requests are always commensurate with new scientific evidence.
Implications for Manufacturers
For manufacturers intending to market Class II–IV devices in Canada, compliance management now spans the entire device lifecycle. With the regulations in effect since January 1, 2026, and the new operational guidance, it is essential to integrate potential Terms and Conditions into post-market surveillance (PMS) and clinical evidence planning, bearing in mind that Health Canada can convert a standard license into a conditional license at any time.
FONTE:
